Dr. Hans M. Sander, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 734
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Texas A & M University System, Hsc, College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Dermatology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Central Texas Community Health Centers (173 clinicians)
- Oliver Street 5.01(a) Inc (168 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 734
- Services billed
- 5,469
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,937 | 324 |
| Established patient office or other outpatient visit, 20-29 minutes | 746 | 525 |
| Destruction of precancer skin growth, 1 growth | 629 | 457 |
| Established patient office or other outpatient visit, 30-39 minutes | 450 | 280 |
| Biopsy of related skin growth, first growth | 362 | 295 |
| Destruction of skin growth, 1-14 growths | 208 | 179 |
| Biopsy of related skin growth, each additional growth | 167 | 89 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 95 | 53 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 78 | 71 |
| Injection of drug or substance under skin or into muscle | 62 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Austin, TX | 287 |
| Minoxidil Other prescribers in Austin, TX | 130 |
| Doxycycline Hyclate Other prescribers in Austin, TX | 103 |
| Triamcinolone Acetonide Other prescribers in Austin, TX | 98 |
| Finasteride Other prescribers in Austin, TX | 91 |
| Mupirocin Other prescribers in Austin, TX | 85 |
| Betamethasone Dipropionate Other prescribers in Austin, TX | 82 |
| Dupixent Pen (dupilumab) Other prescribers in Austin, TX | 75 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 68 |
| Gabapentin Other prescribers in Austin, TX | 55 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 286 payments worth $5,842 in total to this clinician.
| Janssen Biotech, Inc. | $1,131 |
|---|---|
| AbbVie Inc. | $1,026 |
| Genzyme Corporation | $502 |
| Novartis Pharmaceuticals Corporation | $328 |
| Arcutis Biotherapeutics, Inc. | $308 |
| UCB, Inc. | $295 |
| Pfizer Inc. | $255 |
| Sun Pharmaceutical Industries Inc. | $254 |
| Food and Beverage | $5,787 |
|---|---|
| Education | $54.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 9, 2025 | Education TREMFYA · Immunology · in-kind | $54.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $72,132 in research payments for these studies, mostly to the institutions running them.
- The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Incyte Corporation - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Sanofi US Services Inc. · Terminated · NCT06058156
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.